Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Zentalis Pharmaceuticals (ZNTL) Return on Invested Capital (2022 - 2025)

Zentalis Pharmaceuticals (ZNTL) has 4 years of Return on Invested Capital data on record, last reported at 0.63% in Q3 2025.

  • For Q3 2025, Return on Invested Capital fell 6.0% year-over-year to 0.63%; the TTM value through Sep 2025 reached 0.63%, down 6.0%, while the annual FY2024 figure was 0.49%, 19.0% up from the prior year.
  • Return on Invested Capital reached 0.63% in Q3 2025 per ZNTL's latest filing, up from 0.64% in the prior quarter.
  • Across five years, Return on Invested Capital topped out at 0.53% in Q2 2024 and bottomed at 0.67% in Q1 2025.
  • Average Return on Invested Capital over 4 years is 0.59%, with a median of 0.57% recorded in 2023.
  • Peak YoY movement for Return on Invested Capital: fell -12bps in 2023, then rose 10bps in 2024.
  • A 4-year view of Return on Invested Capital shows it stood at 0.53% in 2022, then decreased by -24bps to 0.65% in 2023, then increased by 15bps to 0.55% in 2024, then fell by -13bps to 0.63% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Invested Capital were 0.63% in Q3 2025, 0.64% in Q2 2025, and 0.67% in Q1 2025.